Dianthus Therapeutics Files 8-K for 'Other Event' on March 26, 2026

Ticker: DNTH · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001690585

Dianthus Therapeutics, INC. /De/ 8-K Filing Summary
FieldDetail
CompanyDianthus Therapeutics, INC. /De/ (DNTH)
Form Type8-K
Filed DateMar 26, 2026
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentmixed

Complexity: simple

Sentiment: mixed

Topics: other-event, regulatory-filing

TL;DR

**Dianthus Therapeutics just dropped an 8-K for an 'Other Event' on March 26, 2026; details are key, so dig in!**

AI Summary

Dianthus Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 8.01, indicating an 'Other Event' and including an exhibit EX-99.1. While the specific details of the event are not provided in the summary, the filing suggests a significant, non-routine occurrence that the company deemed important enough to disclose immediately. This matters to investors because 'Other Events' can range from positive developments like clinical trial successes to negative ones like regulatory setbacks, directly impacting the stock's future value.

Why It Matters

This filing signals a material event at Dianthus Therapeutics, Inc. that could influence its operations, financial health, or strategic direction, making it crucial for current and prospective shareholders to investigate further.

Risk Assessment

Risk Level: medium — The 'Other Event' nature of the filing means the specific impact is unknown, creating uncertainty that could lead to stock volatility.

Analyst Insight

A smart investor would immediately review Exhibit EX-99.1 to understand the specific details of the 'Other Event' reported by Dianthus Therapeutics, Inc. before making any investment decisions, as the nature of such an event can significantly impact the company's valuation.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

What is the specific nature of the 'Other Event' reported by Dianthus Therapeutics, Inc. in this 8-K filing?

The filing itself, specifically Item 8.01, only states 'Other Events' and refers to Exhibit EX-99.1 for details. The provided text does not elaborate on the specific nature of this event, requiring further review of the exhibit.

When was this 8-K filing submitted and accepted by the SEC?

The 8-K filing by Dianthus Therapeutics, Inc. was filed and accepted on March 26, 2026, at 08:00:19.

What is the purpose of Item 9.01 in this 8-K filing?

Item 9.01 of this 8-K filing is for 'Financial Statements and Exhibits,' indicating that the filing includes relevant financial information or supporting documents, such as EX-99.1.

How many documents are included in this specific 8-K filing?

This 8-K filing includes 94 documents, as indicated by the 'Documents' count on the filing detail page.

What is the accession number for this 8-K filing?

The SEC Accession No. for this 8-K filing is 0001690585-26-000010.

Filing Stats: 594 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2026-03-26 08:00:19

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On March 26, 2026, Dianthus Therapeutics, Inc. (the "Company") posted an updated corporate presentation (the "Presentation") on the investor relations section of its website. The Presentation is filed as Exhibit 99.1 and is incorporated by reference into this Item 8.01. In addition, in the first quarter of 2026, the Company proposed to the Food & Drug Administration ("FDA") the following changes to screening criteria and required routine labs, and the description of the hypothetical autoimmune safety risk across claseprubart clinical trials, based on patient experience to date and scientific consensus from published data: 1. Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs; 2. Removal of routine ANA testing during claseprubart clinical trials; and 3. Reclassification of the hypothetical risk of systemic lupus erythematosus ("SLE") to drug-induced lupus ("DIL"), a side effect in several classes of widely used medications characterized by the reversal of symptoms upon discontinuation of the precipitating medication. In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials. Of note there have been no cases of either SLE or DIL to date in any claseprubart program.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate Presentation of Dianthus Therapeutics, Inc., dated March 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: March 26, 2026 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing